Aravax’s peanut allergy treatment avoids whole allergens. FDA Fast Track status puts its biggest test in focus
Aravax has secured United States Food and Drug Administration Fast Track designation for PVX108, an investigational peptide immunotherapy designed to retrain peanut-specific immune responses without containing whole peanut proteins or allergen extracts. The regulatory milestone increases the importance of Phase 2 results expected later in 2026.
